Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SISamad IbitokouBHBryan HancockTDTom Daily

Discussion

Loading...

Member takes

Overview

Findings demonstrate enhanced cytotoxicity of CAR T cells targeting CD38 and MICA/B in multiple myeloma, suggesting improved therapeutic options.

Key Points

  • This research aims to develop a novel CAR T-cell therapy that targets CD38 and MICA/B to treat multiple myeloma more effectively.
  • Utilized FT836, an iPSC-derived CAR T cell targeting MICA/B and CD38 antigens.
  • Conducted in vitro cytotoxicity assays with therapeutic monoclonal antibodies like daratumumab.
  • Evaluated the efficacy in a xenograft model of solid tumors.
  • FT836 demonstrated dose-dependent killing in combination with daratumumab.
  • Enhanced functional persistence and reduced alloreactive immune cell generation were observed with FT836.
  • Significant tumor control was achieved in xenograft models when combined with therapeutic antibodies.

Cite This Study

Ibitokou et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d06chttps://doi.org/10.1182/blood-2025-2350
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma2025
  2. 2Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  3. 3CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  4. 4The allogeneic fully human anti-CD38-CAR-γδ T cells enable off-the-shelf CAR-T cell therapy for myeloma2025
  5. 5[Next-generation CAR gene-modified cell therapy: overcoming resistance and exploring novel applications].2025